ADC Therapeutics SA
ADCT
ADCT: ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
moreShow ADCT Financials
Recent trades of ADCT by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ADCT's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Combination therapy with an anti-cd25 antibody-drug conjugate Mar. 07, 2023
-
Patent Title: Dosage regimes for the administration of an anti-cd25 adc Aug. 30, 2022
-
Patent Title: Pyrrolobenzodiazepine-antibody conjugates Jul. 12, 2022
-
Patent Title: Dosage regimes for the administration of an anti-cd19 adc May. 03, 2022
-
Patent Title: Pyrrolobenzodiazepine-antibody conjugates Nov. 02, 2021
-
Patent Title: Method for treating breast cancer Aug. 10, 2021
-
Patent Title: Pyrrolobenzodiazepine-antibody conjugates Oct. 13, 2020
-
Patent Title: Pyrrolobenzodiazepine-antibody conjugates Sep. 22, 2020
-
Patent Title: Pyrrolobenzodiazepine-anti-cd22 antibody conjugates Jul. 28, 2020
-
Patent Title: Combination therapy with an anti-axl antibody-drug conjugate Jan. 28, 2020
-
Patent Title: Pyrrolobenzodiazepine-anti-cd22 antibody conjugates Mar. 20, 2018
-
Patent Title: Anti-kidney associated antigen 1 (kaag1) antibodies Jan. 02, 2018
-
Patent Title: Antibodies against kidney associated antigen 1 and antigen binding fragments thereof Nov. 28, 2017
Federal grants, loans, and purchases
Followers on ADCT's company Twitter account
Number of mentions of ADCT in WallStreetBets Daily Discussion
Recent insights relating to ADCT
Recent picks made for ADCT stock on CNBC
ETFs with the largest estimated holdings in ADCT
Flights by private jets registered to ADCT